首頁 > 市場調查報告書 > 製藥

疼痛

市場調查報告書

商品編碼

1747115

日本疼痛管理藥物市場規模、佔有率、趨勢及預測（按藥品類別、適應症、配銷通路和地區分類），2025 年至 2033 年

Japan Pain Management Drugs Market Size, Share, Trends and Forecast by Drug Class, Indication, Distribution Channel, and Region, 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 116 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本疼痛管理藥物市場規模達42.2267億美元。展望未來， IMARC Group預計到2033年，市場規模將達到52.0448億美元，2025-2033年期間的複合年成長率（CAGR）為2.35%。受人口老化、藥物輸送創新以及非鴉片類藥物治療需求成長的推動，日本市場正經歷顯著成長。此外，嚴格的監管和醫療改革持續影響全國市場擴張和治療的進步。

日本疼痛管理藥物市場趨勢：

老年人口不斷增加

日本人口老化是疼痛管理藥物產業持續需求的重要驅動力。老年人口的不斷成長直接影響著日本疼痛管理藥物市場的成長，因為與年齡相關的健康問題，例如骨關節炎、慢性背痛和神經性疾病變得越來越普遍。據報道，日本老年人口達到創紀錄的3,625萬，佔總人口的29.3%。 65歲以上女性佔2053萬，男性佔1572萬人。此外，914萬老年人就業，反映出隨著人口連續13年下降，人口結構面臨的挑戰仍在持續。日本的預期壽命位居全球前列，很大一部分人口需要長期持續的疼痛緩解療法。這些療法通常包括非類固醇抗發炎藥、抗憂鬱藥物以及針對老年人的專門治療，而老年人也更容易受到藥物敏感性和副作用的影響。醫療保健提供者正在透過優先考慮更安全、更低劑量的製劑和監測方案來適應這種情況。此外，與年齡相關的手術（例如關節置換術）的增多，也刺激了術後止痛藥的需求。隨著日本人口結構轉變的加深，此趨勢將持續提升日本疼痛管理藥物在各類治療領域的市場佔有率。

藥物輸送和配方的創新

日本製藥公司正積極創新給藥方式，以改善治療效果並提升患者舒適度。隨著對慢性疼痛和老年護理的日益關注，各公司正轉向透皮貼片、緩釋片以及外用凝膠或噴霧等先進技術。這些替代方案能夠實現更精準的給藥、持續的疼痛緩解，並減少胃腸道或全身副作用，這對老年人和長期用藥者尤其重要。製劑創新還包括開發複方藥物和新型化合物，以更有效地緩解疼痛並降低依賴風險。例如，2024年11月，衛材株式會社在日本推出了注射用Rozebalamin(R) 25毫克（甲鈷胺），用於減緩肌萎縮側索硬化症(ALS)患者的功能障礙並緩解疼痛。該藥物於9月獲得批准，此前已進行130名患者的III期臨床試驗。這些進步不僅提高了患者的依從性，也擴展了跨治療類別的產品供應。隨著監管機構支持更安全的替代品，醫療保健專業人員採用更新的交付方式，創新預計將在未來幾年塑造日本疼痛管理藥物市場前景方面發揮關鍵作用。

日本疼痛管理藥物市場區隔：

藥物類別洞察：

非類固醇抗發炎藥
麻醉藥
抗驚厥藥
抗偏頭痛藥物
抗憂鬱藥
鴉片類藥物
其他

指示見解：

肌肉骨骼疼痛
手術和創傷疼痛
癌症痛
神經性疼痛
偏頭痛
產科疼痛
纖維肌痛
燒傷痛
牙齒/臉部疼痛
兒童疼痛
其他

配銷通路洞察：

醫院藥房
零售藥局
網路藥局

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本疼痛管理藥物市場迄今表現如何？未來幾年將如何表現？
根據藥品類別，日本疼痛管理藥物市場是如何分類的？
日本疼痛管理藥物市場根據適應症的分類是怎樣的？
根據配銷通路，日本疼痛管理藥物市場是如何分類的？
日本疼痛管理藥物市場按地區分類的分佈如何？
日本疼痛管理藥物市場的價值鏈分為哪些階段？
日本疼痛管理藥物市場的主要促進因素和挑戰是什麼？
日本疼痛管理藥物市場的結構是怎麼樣的？主要參與者是誰？
日本疼痛管理藥物市場的競爭程度如何？

本報告回答的關鍵問題：

日本疼痛管理藥物市場迄今表現如何？未來幾年將如何表現？
根據藥品類別，日本疼痛管理藥物市場是如何分類的？
日本疼痛管理藥物市場根據適應症的分類是怎樣的？
根據配銷通路，日本疼痛管理藥物市場是如何分類的？
日本疼痛管理藥物市場按地區分類的分佈如何？
日本疼痛管理藥物市場的價值鏈分為哪些階段？
日本疼痛管理藥物市場的主要促進因素和挑戰是什麼？
日本疼痛管理藥物市場的結構是怎麼樣的？主要參與者是誰？
日本疼痛管理藥物市場的競爭程度如何？

The Japan pain management drugs market size reached USD 4,222.67 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 5,204.48 Million by 2033, exhibiting a growth rate (CAGR) of 2.35% during 2025-2033. The market is experiencing significant growth, driven by an aging population, innovation in drug delivery, and rising demand for non-opioid treatments. Moreover, strict regulations and healthcare reforms continue to shape market expansion and therapeutic advancements nationwide.

Japan Pain Management Drugs Market Trends:

Rising Geriatric Population

Japan's aging population is a significant driver of sustained demand in the pain management drugs industry. The increasing number of elderly individuals is directly influencing Japan pain management drugs market growth, as age-related health issues such as osteoarthritis, chronic back pain, and neuropathic conditions become more prevalent. According to the reports, Japan's elderly population reached a record 36.25 million, making up 29.3% of the total population. Women aged 65 or older account for 20.53 million, while men total 15.72 million. Additionally, 9.14 million elderly are employed, reflecting ongoing demographic challenges as the population declines for the 13th consecutive year. With life expectancy among the highest globally, a large segment of the population requires long-term, consistent pain relief therapies. These often include a combination of NSAIDs, antidepressants, and specialized treatments tailored to older adults, who are also more vulnerable to drug sensitivity and side effects. Healthcare providers are adapting by prioritizing safer, lower-dose formulations and monitoring protocols. Additionally, the rising rate of age-related surgeries, such as joint replacements, is fueling demand for post-operative pain medications. As Japan's demographic shift deepens, this trend will continue to increase the Japan pain management drugs market share across therapeutic categories.

Innovation in Drug Delivery and Formulation

Japanese pharmaceutical companies are actively innovating drug delivery methods to improve treatment outcomes and enhance patient comfort. With a growing focus on chronic pain and elderly care, firms are shifting toward advanced options such as transdermal patches, extended-release tablets, and topical gels or sprays. These alternatives allow for more precise dosing, sustained pain relief, and reduced gastrointestinal or systemic side effects, which are particularly important for older adults and long-term users. Innovation in formulation also includes development of combination drugs and novel compounds that target pain more efficiently while reducing dependency risks. For instance, in November 2024, Eisai Co., Ltd. launched Rozebalamin(R) for Injection 25 mg (mecobalamin) in Japan, to slow functional impairment and address pain in amyotrophic lateral sclerosis (ALS) patients. Approved in September, it follows a Phase III trial with 130 patients. These advancements are not only improving adherence but also expanding product offerings across therapeutic categories. As regulatory bodies support safer alternatives and healthcare professionals adopt newer delivery formats, innovation is expected to play a key role in shaping the Japan pain management drugs market outlook in the coming years.

Japan Pain Management Drugs Market Segmentation:

Drug Class Insights:

NSAIDs
Anesthetics
Anticonvulsants
Antimigraine Agents
Antidepressants
Opioids
Others

Indication Insights:

Musculoskeletal Pain
Surgical and Trauma Pain
Cancer Pain
Neuropathic Pain
Migraine Pain
Obstetrical Pain
Fibromyalgia Pain
Burn Pain
Dental/Facial Pain
Pediatric Pain
Others

Distribution Channel Insights:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan pain management drugs market performed so far and how will it perform in the coming years?
What is the breakup of the Japan pain management drugs market on the basis of drug class?
What is the breakup of the Japan pain management drugs market on the basis of indication?
What is the breakup of the Japan pain management drugs market on the basis of distribution channel?
What is the breakup of the Japan pain management drugs market on the basis of region?
What are the various stages in the value chain of the Japan pain management drugs market?
What are the key driving factors and challenges in the Japan pain management drugs market?
What is the structure of the Japan pain management drugs market and who are the key players?
What is the degree of competition in the Japan pain management drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pain Management Drugs Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Pain Management Drugs Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Pain Management Drugs Market - Breakup by Drug Class

6.1 NSAIDs
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Anesthetics
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Anticonvulsants
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Antimigraine Agents
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Antidepressants
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2019-2024)
- 6.5.3 Market Forecast (2025-2033)
6.6 Opioids
- 6.6.1 Overview
- 6.6.2 Historical and Current Market Trends (2019-2024)
- 6.6.3 Market Forecast (2025-2033)
6.7 Others
- 6.7.1 Historical and Current Market Trends (2019-2024)
- 6.7.2 Market Forecast (2025-2033)

7 Japan Pain Management Drugs Market - Breakup by Indication

7.1 Musculoskeletal Pain
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Surgical and Trauma Pain
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Cancer Pain
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Neuropathic Pain
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Migraine Pain
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
7.6 Obstetrical Pain
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2019-2024)
- 7.6.3 Market Forecast (2025-2033)
7.7 Fibromyalgia Pain
- 7.7.1 Overview
- 7.7.2 Historical and Current Market Trends (2019-2024)
- 7.7.3 Market Forecast (2025-2033)
7.8 Burn Pain
- 7.8.1 Overview
- 7.8.2 Historical and Current Market Trends (2019-2024)
- 7.8.3 Market Forecast (2025-2033)
7.9 Dental/Facial Pain
- 7.9.1 Overview
- 7.9.2 Historical and Current Market Trends (2019-2024)
- 7.9.3 Market Forecast (2025-2033)
7.10 Pediatric Pain
- 7.10.1 Overview
- 7.10.2 Historical and Current Market Trends (2019-2024)
- 7.10.3 Market Forecast (2025-2033)
7.11 Others
- 7.11.1 Historical and Current Market Trends (2019-2024)
- 7.11.2 Market Forecast (2025-2033)

8 Japan Pain Management Drugs Market - Breakup by Distribution Channel

8.1 Hospital Pharmacies
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Retail Pharmacies
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Online Pharmacies
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)

9 Pediatric Pain

7.9.1 Overview
7.9.2 Historical and Current Market Trends (2019-2024)
7.9.3 Market Forecast (2025-2033)

7.10 Others
- 7.10.1 Historical and Current Market Trends (2019-2024)
- 7.10.2 Market Forecast (2025-2033)

8 Japan Pain Management Drugs Market - Breakup by Distribution Channel

8.1 Hospital Pharmacies
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Retail Pharmacies
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Online Pharmacies
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)

9 Japan Pain Management Drugs Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Products Offered
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Products Offered
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Products Offered
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Products Offered
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Products Offered
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Pain Management Drugs Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis